CV Risk Assessment For All Obesity Drugs Seems Inevitable Pre-Approval Requirement
This article was originally published in The Pink Sheet Daily
FDA’s Endocrinologic and Metabolic Drugs Advisory Committee March 29 voted 17-6 that all obesity drugs should be vetted for cardiovascular risk, but some could rely on a meta-analysis rather than an outcomes trial.
You may also be interested in...
The biotech disclosed in an SEC filing that its obesity drug may actually provide a cardiovascular benefit to patients based on early results from an ongoing outcomes study.
As a reviewer, team leader and deputy director in the Division of Metabolism and Endocrinology Products, Colman spearheaded the agency’s policy development on weight-management products.
If cardiovascular studies are required for non-cardiac drugs, they should be focused on specific signals of heart-related concern that may not include ischemic events, advisory committee cardiologists say during review of Novo Nordisk’s Saxenda for obesity.